Status:
UNKNOWN
COVID19-hematological Malignancies: the Italian Hematology Alliance
Lead Sponsor:
Ospedale di Circolo - Fondazione Macchi
Conditions:
SARS-CoV-2 Infection
Hematological Malignancies
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective/prospective, cohort, non-interventional observational study. This means that all patients with documented COVID and HM diagnosed between February 2020 and study initiation will...
Detailed Description
This is a retrospective/prospective, cohort, non-interventional observational study. An informed consensus for the participation is available. In this section we provide informations on sample size an...
Eligibility Criteria
Inclusion
- Age equal to or greater than 18 years of age.
- History of hematological malignancies (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma).
- Active hematological malignancies (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma) at any stage/status.
- SARS-CoV-2 positive test (nasopharyngeal, BAL, fecal), documented by Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panels.
Exclusion
- Hematological diseases, other than hematological malignancies.
- SARS-CoV-2 negative test.
Key Trial Info
Start Date :
April 7 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04352556
Start Date
April 7 2020
End Date
October 1 2022
Last Update
September 23 2022
Active Locations (81)
Enter a location and click search to find clinical trials sorted by distance.
1
SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
2
UOC Ematologia, Ospedali Riuniti
Ancona, Italy
3
UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni
Ascoli Piceno, Italy
4
SC Oncologia Medica, CRO
Aviano, Italy